Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

119 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Accuracy of Multiple Blood Tests to Diagnose Sepsis in Adult Burn Patients

NCT07126574

Sepsis - to Reduce Mortality in the Intensive Care Unit Burns Involving 20% or More of Body Surface

NOT_YET_RECRUITING

Systems Analysis of Antigen Presenting Cells in Human Sepsis

NCT03788772

Sepsis Acute Circulatory Failure

COMPLETED NA

Early Diagnostic Biomarkers of Sepsis

NCT05112406

Critically Ill Sepsis

UNKNOWN

Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection

NCT07332793

Sepsis

NOT_YET_RECRUITING

Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

NCT00144638

Sepsis - to Reduce Mortality in the Intensive Care Unit

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Immune Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immunocompetent sepsis patients

Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.

No interventions assigned to this group

Immunocompromised sepsis patients

Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.

No interventions assigned to this group

Patients without sepsis

Patients who admitted intensive care unit without sepsis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged ≥ 19 years
* Appropriate clinical data to enable classification into sepsis
* Written informed consent by the patient or legally authorized representative
* Critical illness consistent with sepsis, to be enrolled within 24 hours of presentation

Exclusion Criteria

* No informed consent
* A patient who is judged to be unable to make a voluntary decision by understanding information about this research due to cognitive vulnerability

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No